Document is current

Article History

Received: 25 August 2024

Accepted: 23 December 2024

First Online: 2 January 2025

Declarations

:

: PV received speaker fees from Heidelberg Engineering GmbH and Bayer. HPNS is supported by the Swiss National Science Foundation (Project funding: “Developing novel outcomes for clinical trials in Stargardt disease using structure/function relationship and deep learning” #310030_201165, and National Center of Competence in Research Molecular Systems Engineering: “NCCR MSE: Molecular Systems Engineering (phase II)” #51NF40-182895, the Wellcome Trust (PINNACLE study), and the Foundation Fighting Blindness Clinical Research Institute (ProgStar study). Dr. Scholl is member of the Scientific Advisory Board of: Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences; Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH; ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc. Dr. Scholl is a consultant of: Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global, LLC; and Tenpoint Therapeutics. Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of Belite Bio (DRAGON trial, NCT05244304; LBS-008-CT02, NCT05266014), F. Hoffmann-La Roche Ltd (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966; HUTONG trial), ViGeneron (protocol number VG901-2021-A) and member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561). PMM is a consultant of Roche and holds intellectual properties for machine learning at MIMO AG and VisionAI, Switzerland. The other authors declare no conflict. Funding organisations had no influence on the design, performance or evaluation of the current study.